vTv Therapeutics (VTVT) Operating Expenses (2014 - 2026)

vTv Therapeutics (VTVT) has 13 years of Operating Expenses data on file, last reported at $13.6 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 108.77% year-over-year to $13.6 million; the trailing twelve-month figure through Mar 2026 stood at $39.9 million (up 59.06% YoY), and the FY2025 full-year result was $32.8 million, up 30.21% from the prior year.
• Operating Expenses climbed to $13.6 million in Q1 2026, from $7.9 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $13.6 million in Q1 2026 to a low of $4.0 million in Q2 2022.
• A 5-year average of $7.2 million and a median of $6.6 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses sank 42.87% in 2022 and jumped 108.77% in 2026, its largest moves.
• Tracing VTVT's Operating Expenses over 5 years: stood at $6.4 million in 2022, then slipped by 25.9% to $4.7 million in 2023, then grew by 4.29% to $4.9 million in 2024, then soared by 60.62% to $7.9 million in 2025, then jumped by 72.18% to $13.6 million in 2026.
• Business Quant data shows VTVT's Operating Expenses at $13.6 million in Q1 2026, $7.9 million in Q4 2025, and $10.7 million in Q3 2025.